What it's for (Indications)
- Fludarabine is indicated for the treatment of patients with B-cell Chronic Lymphocytic Leukemia (CLL).
- This includes patients who have not responded to or whose disease has progressed during treatment with at least one prior standard alkylating agent-containing regimen.
- It is employed to achieve disease remission, which often manifests as a reduction in lymphocyte counts, improvement in organomegaly, and alleviation of constitutional symptoms associated with the disease.
- Its use is specifically targeted at this hematologic malignancy where it has demonstrated efficacy in inducing responses.
- The decision to initiate fludarabine therapy should be made by a healthcare professional experienced in the use of antineoplastic agents, considering the patient's overall clinical status, comorbidities, and prior treatment history.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For the treatment of B-cell Chronic Lymphocytic Leukemia (CLL), the recommended adult dose of fludarabine phosphate is 25 mg/m² administered intravenously (IV) over a period of approximately 30 minutes daily for five consecutive days. This five-day course is typically repeated every 28 days (four weeks). The duration of treatment depends on the patient's response and tolerance to the medication, often continuing until maximal response is achieved, usually after 3-6 cycles. Dosage adjustments are crucial in patients with impaired renal function. For individuals with a creatinine clearance between 30 and 70 mL/min, the dose should be reduced by 20% to 50% depending on the institution's protocol and severity of impairment. Fludarabine is contraindicated in patients with creatinine clearance less than 30 mL/min due to the increased risk of severe toxicity. Close monitoring of renal function, complete blood counts, and other relevant laboratory parameters is essential throughout the treatment course. |
Safety & Warnings
Common Side Effects
- Fludarabine is associated with a wide spectrum of adverse effects, reflecting its potent cytotoxic nature.
- The most prominent and clinically significant adverse reactions include profound myelosuppression, manifesting as neutropenia, thrombocytopenia, and anemia, which can lead to life-threatening infections and bleeding.
- Infections are common, including opportunistic infections such as Pneumocystis jirovecii pneumonia (PJP), viral reactivation (e.
- g.
- , cytomegalovirus, herpes simplex virus), and fungal infections, necessitating prophylactic measures.
- Neurologic toxicities range from mild fatigue and headache to severe, irreversible central nervous system events like peripheral neuropathy, confusion, seizures, visual disturbances (including blindness), and coma, especially at higher doses or in susceptible patients.
- Gastrointestinal disturbances are frequent, encompassing nausea, vomiting, diarrhea, stomatitis, and anorexia.
- Other significant side effects include fever, chills, fatigue, malaise, skin rash, pulmonary infiltrates, and tumor lysis syndrome, which requires vigilant monitoring and management.
- Autoimmune hemolytic anemia and other autoimmune phenomena can also occur.
Serious Warnings
- Black Box Warning: Fludarabine has several serious safety concerns that warrant a Black Box Warning. Severe bone marrow suppression (myelosuppression), including profound neutropenia, thrombocytopenia, and anemia, is a dose-limiting toxicity and a major concern. This can lead to severe infections, including opportunistic pathogens, and hemorrhagic complications, which may be fatal. Furthermore, severe neurotoxicity, encompassing irreversible central nervous system effects such as blindness, coma, and death, has been reported, particularly when fludarabine is administered at high doses or for prolonged periods, or in patients with impaired renal function. Patients should be closely monitored for signs and symptoms of neurologic dysfunction. Autoimmune phenomena, including life-threatening or fatal autoimmune hemolytic anemia, pure red cell aplasia, immune thrombocytopenia, and Evan's syndrome, have occurred and can be severe. Close monitoring for these manifestations is essential, and treatment should be discontinued upon their occurrence. Lastly, cases of tumor lysis syndrome have been observed in patients with a large tumor burden, which can lead to acute renal failure, arrhythmias, and death. Adequate hydration and allopurinol prophylaxis are critical in these patients.
- Beyond the specific cautions highlighted in the Black Box Warning, several other critical warnings are associated with fludarabine therapy.
- Due to its potent immunosuppressive effects, patients are at a significantly increased risk of severe and opportunistic infections.
- Prophylactic anti-infective agents, particularly for Pneumocystis jirovecii pneumonia, are strongly recommended during and after treatment.
- There is an increased risk of developing autoimmune phenomena, such as autoimmune hemolytic anemia, pure red cell aplasia, and immune thrombocytopenia, which may be severe or life-threatening; these require immediate recognition and management, including discontinuation of fludarabine.
- Patients receiving fludarabine should not receive live attenuated vaccines due to the risk of severe or fatal infection.
- Furthermore, transfusion-associated graft-versus-host disease (TA-GVHD) can occur following transfusion of un-irradiated blood products, necessitating the use of irradiated blood for all patients undergoing fludarabine therapy.
- Secondary malignancies, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), have been reported.
- Renal function must be carefully assessed and monitored, with dose adjustments imperative for patients with impaired creatinine clearance, and the drug is contraindicated in severe renal impairment.
- Careful consideration of hepatic function is also advised.
How it Works (Mechanism of Action)
Fludarabine phosphate is a purine analog, specifically a fluorinated nucleotide analog of adenosine. It acts as a prodrug that is rapidly dephosphorylated in the plasma to 2-fluoro-ara-A (F-ara-A), which is then transported into cells. Inside the cell, F-ara-A is phosphorylated by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP (F-ara-ATP). This active metabolite is a potent inhibitor of DNA synthesis and, to a lesser extent, RNA synthesis. F-ara-ATP primarily interferes with several key enzymes involved in DNA replication and repair, including DNA polymerase-alpha, -delta, and -epsilon, ribonucleotide reductase, and DNA primase. By inhibiting ribonucleotide reductase, it depletes intracellular deoxyribonucleotide triphosphate pools. Furthermore, F-ara-ATP is incorporated into both DNA and RNA, leading to premature chain termination and disruption of macromolecular synthesis and function. This multifaceted action results in the accumulation of DNA strand breaks and ultimately triggers apoptosis in both actively proliferating and quiescent malignant lymphoid cells, particularly those found in chronic lymphocytic leukemia.
Commercial Brands (Alternatives)
No other brands found for this formula.